Table 2.

Transplant outcomes between patients who underwent Haplo-SCT and those who received MSDT

Parameter	Haplo-SCT group (n = 169)	MSDT group (n = 39)	P value
Median time of neutrophil engraftment (range)	13 days (10–25 days)	15 days (9–22 days)	0.016
Platelet engraftment at day 100 post-transplantation	95% (95% CI, 92–98%)	100%	< 0.001
CMV reactivation at day 100 post-transplantation	68% (95% CI, 61–75%)	18% (95% CI, 6–30%)	< 0.001
EBV reactivation at day 100 post-transplantation	15% (95% CI, 10–21%)	0	0.011
Grades II–IV acute GVHD	21% (95% CI, 17–27%)	23% (95% CI, 10–36%)	0.884
Total chronic GVHD	44% (95% CI, 36–52%)	48% (95% CI, 31–65%)	0.850
Moderate-to-severe chronic GVHD	18% (95% CI, 10–26%)	27% (95% CI, 10–44%)	0.192
Cumulative incidence of positive MRD after transplantation	26% (95% CI, 19–33%)	44% (95% CI, 28–60%)	0.043
Three-year probability of relapse	23% (95% CI, 17–29%)	47% (95% CI, 31–63%)	0.006
Three-year probability of NRM	11% (95% CI, 6–16%)	10% (95% CI, 1–19%)	0.845
Three-year probability of LFS	65% (95% CI, 58–72%)	43% (95% CI, 27–59%)	0.023
Three-year probability of OS	68% (95% CI, 61–75%)	46% (95% CI, 30–62%)	0.039
Three-year probability of GRFS	54% (95% CI, 46–62%)	36% (95% CI, 21–51%)	0.055

Haplo-SCT haploidentical stem cell transplantation, MSDT human leukocyte antigen-matched sibling donor transplantation, CI confidence interval, GVHD graft-versus-host disease, MRD measurable residual disease, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival